Menu Search
Equities

Northwest Biotherapeutics Inc

NWBO:QBB

Northwest Biotherapeutics Inc

Actions
  • Price (USD)0.32
  • Today's Change0.012 / 3.90%
  • Shares traded1.27m
  • 1 Year change-61.21%
  • Beta-0.5860
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Northwest Biotherapeutics Inc grew revenues 14.80% from 1.68m to 1.93m while net income improved from a loss of 105.03m to a smaller loss of 62.60m.
Gross margin--
Net profit margin-4,479.03%
Operating margin-4,181.34%
Return on assets-260.06%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at Northwest Biotherapeutics Inc fell by 4.84m. Cash Flow from Financing totalled 52.76m or 2,730.75% of revenues. In addition the company used 53.64m for operations while cash used for investing totalled 3.44m.
Cash flow per share-0.0629
Price/Cash flow per share--
Book value per share-0.047
Tangible book value per share-0.0485
More ▼

Balance sheet in USDView more

Northwest Biotherapeutics Inc uses little or no debt in its capital structure.
Current ratio0.0886
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.